Resident Doctors are on strike from 7 - 13 April. Please continue to attend appointments at the hospital unless you are contacted directly to rearrange. Our hospitals will be busy, but we are still here to provide emergency care when you need it.

Team One Oncology Research

We cover phase II-III research trials in the following disease areas: Lung, Renal, Bladder, Prostate, Neuro-Oncology, Melanoma and Head and Neck.

Our aim is to have a varied portfolio that allows all patients in these areas to access and participate in research.

We are patient-centred and work collaboratively within the team, with patients and with clinicians. We are committed to excellence in health research, providing equal opportunities for treatments for all our patients.

Current research studies

We have various recruiting studies with many more in setup. Below is a list of current recruiting studies.

  • EPIC: A Phase II Trial of Cemiplimab alone or in combination with Standard of Care Chemotherapy in Locally Advanced or Metastatic Penile Carcinoma. PI: Dr Helen Dearden
  • DISCUS: A randomised phase II study comparing 3 vs 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer. PI: Dr Naveen Vasudev
  • GUSTO: a multicentre, prospective, open-label, individually randomised, controlled, parallel-group, multi-stage phase II trial of patients with T2-4a N0 M0 MIBC or T(any) N1 M0 MIBC who are suitable for NAC with cisplatin and gemcitabine prior to radical cystectomy. PI: Dr Helen Dearden
  • Refine Renal: A multi-arm phase II basket protocol testing reduced intensity immunotherapy across different cancers. PI: Dr Christy Ralph
  • Pacific-4: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer. PI: Dr Kevin Franks
  • Pacific-8: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy. PI: Dr Mark Teo
  • eVolve-MESO: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Malignant Pleural Mesothelioma. PI: Dr Dan Lee
  • Refine Lung: A randomised open-label phase III trial of Reduced Frequency pembrolizumab immuNothErapy for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm frequency-response optimisation design. PI: Dr Pooja Jain
  • Harmony: A Phase 3 Trial of Fianlimab (REGN3767, ANTI-LAG-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma. PI: Dr Jane Hook
  • Immunocore: Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM). PI: Dr Maria Marples
  • Impact: Efficacy and safety of first line Cemiplimab in advanced BCC: A phase 2 trial. PI: Dr Shirin Namini
  • SCOPE: A Phase 2, Multicentre, Open-Label, Umbrella Study of SCIB1 and iSCIB1+ in Patients with Advanced Unresectable Melanoma Receiving Either Nivolumab with Ipilimumab or SCIB1 with Pembrolizumab. PI: Dr Maria Marples
  • MelMarT-II: Melanoma Margins Trial (MelMarT): A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma. PI: Dr Howard Peach
  • ONC-201: ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. PI: Prof Susan Short
  • SPARTA: Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors. PI: Dr Fiona Collinson
  • ARISTOCRAT: A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma. PI: Dr Fiona Collinson

ICI-Genetics – Identification of genetic factors that predispose to immune checkpoint inhibitor toxicity. PI: Dr Danny Ullahannan

How to contact the team

Email address
[email protected]
Phone number
0113 2068811
  • Page last reviewed: